Sjogren’s syndrome is an autoimmune disease which affects exocrine glands, mainly salivary and lacrimal glands, which eventually leads to xerostomia (dryness of mouth) and xerophthalmia (dryness of eyes). Prevalence of the syndrome is higher in female as compared to male. Generally it is observed in age group above 40 years but in cases it has also been observed among children. The syndrome is also found to be associated with abnormality in connective tissue which leads to rheumatoid arthritis and systemic lupus erythematous. Sjogren’s syndrome leads to various complications such as streptococcal, staphylococcal and pneumococcal infections of parotid glands and in some cases it lead to development of parotid tumor. Complications of lymphomas and neuropathy are also seen in patients with vitamin D deficiency. Although exact cause of the syndrome is unknown, scientists believe it to be a hereditary disorder. Sjogren’s syndrome is of two type’s viz. Primary sjogren’s syndrome and secondary sjogren’s syndrome both being systemic disease can affect various systems in body.
Sjogren’s Syndrome Market: Drivers and Restraints
Rising number of patient with sjogren’s syndrome, increasing awareness about syndrome, growing patient population of several diseases that can causes sjogren’s syndrome such as lupus and rheumatoid arthritis, rising demand for advanced treatment for sjogren’s syndrome, growing geriatric population, increasing research and development activities and government initiative are some of the factors that drive the growth of the sjogren’s syndrome treatment market.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1424
Sjogren’s Syndrome Market: Segmentation
Sjogren’s syndrome market is classified on the basis of indication, distribution channel and geography.
Based on the indication type, the global Sjogren ’s syndrome market is segmented into the following:
- Primary Sjogren’s Syndrome
- Secondary Sjogren’s Syndrome
Based on the distribution channel, the global Sjogren ’s syndrome market is segmented into the following:
- Hospitals Clinics
- Public Hospitals
- Private Clinics
- Retail Pharmacies and Drug Stores
Sjogren’s Syndrome Market: Overview
Most of the therapeutics for the sjogren’s syndrome are under clinical trials, rigorous research and development activities will launch innovative treatments. The market is expected to grow in North America and Europe regions as compared to Asia-Pacific, Middle East and Africa owing to higher prevalence rate. More epidemiological studies will revile prevalent regions to be tapped in the near future. The companies operating in dry eye condition, symptom of sjogren’s syndrome are entering into the mergers and acquisition with other companies to expand its product offerings in dry eye syndrome treatment segment. For instant, in 2014, Nicox S.A. a pharmaceutical company based in France launched AdenoPlus and Xailin. In addition, in June 2015, Allergan plc, completed acquisition of Oculeve Inc, a medical device company that emphases on novel technologies for dry eye to develop its business in the dry eye syndrome treatment market. In October 2015, Allergan, Inc. introduced synthetic tear REFRESH OPTIVE gel drops to deliver artificial tear alternative for relieving dry eye symptoms.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1424
Sjogren’s Syndrome Market: Region-wise Outlook
Depending on geographic regions, global sjogren’s syndrome treatment market is segmented into seven regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. The global sjogren’s syndrome treatment market is anticipated to register a healthy CAGR during the forecast period. North America followed by Europe dominates the global sjogren’s syndrome treatment market due to increasing number of geriatric population with sjogren’s syndrome and deployment of advanced healthcare infrastructure facilities. Asia-Pacific is emerging market for global sjogren’s syndrome treatment market due to developing healthcare infrastructure, rise in cases of sjogren’s syndrome, increasing disposable income and rising patient population suffering from autoimmune disease that can cause sjogren’s syndrome and rising government spending in healthcare industry in this region.
Sjogren’s Syndrome Market: Key Players
Some of the key market players in treating symptoms of sjogren’s syndrome market are Novartis AG, Allergan Inc., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Nicox S.A., Argentis Pharmaceuticals, LLC., Auven Therapeutics, Bridge Pharma Inc. and Cellzome GmbH.